Annual Research Review: Prevention of psychosis in adolescents - systematic review and meta-analysis of advances in detection, prognosis and intervention / Ana CATALAN in Journal of Child Psychology and Psychiatry, 62-5 (May 2021)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 62-5 (May 2021) . - p.657-673 Titre : Annual Research Review: Prevention of psychosis in adolescents - systematic review and meta-analysis of advances in detection, prognosis and intervention Type de document : Texte imprimé et/ou numérique Auteurs : Ana CATALAN, Auteur ; Gonzalo SALAZAR DE PABLO, Auteur ; Julio VAQUERIZO SERRANO, Auteur ; Pierluca MOSILLO, Auteur ; Helen BALDWIN, Auteur ; Aranzazu FERNANDEZ-RIVAS, Auteur ; Carmen MORENO, Auteur ; Celso ARANGO, Auteur ; Christoph U CORRELL, Auteur ; Ilaria BONOLDI, Auteur ; Paolo FUSAR-POLI, Auteur Article en page(s) : p.657-673 Langues : Anglais (eng) Mots-clés : Psychosis  adolescence  childhood  clinical high-risk state for psychosis  evidence  first-episode  meta-analysis  prediction  prevention  psychosis risk  schizophrenia Index. décimale : PER Périodiques Résumé : BACKGROUND: The clinical high-risk state for psychosis (CHR-P) paradigm has facilitated the implementation of psychosis prevention into clinical practice; however, advancements in adolescent CHR-P populations are less established. METHODS: We performed a PRISMA/MOOSE-compliant systematic review of the Web of Science database, from inception until 7 October 2019, to identify original studies conducted in CHR-P children and adolescents (mean age <18 years). Findings were systematically appraised around core themes: detection, prognosis and intervention. We performed meta-analyses (employing Q statistics and I (2) test) regarding the proportion of CHR-P subgroups, the prevalence of baseline comorbid mental disorders, the risk of psychosis onset and the type of interventions received at baseline. Quality assessment and publication bias were also analysed. RESULTS: Eighty-seven articles were included (n = 4,667 CHR-P individuals). Quality of studies ranged from 3.5 to 8 (median 5.5) on a modified Newcastle-Ottawa scale. Detection: Individuals were aged 15.6 ± 1.2 years (51.5% males), mostly (83%) presenting with attenuated positive psychotic symptoms. CHR-P psychometric accuracy improved when caregivers served as additional informants. Comorbid mood (46.4%) and anxiety (31.4%) disorders were highly prevalent. Functioning and cognition were impaired. Neurobiological studies were inconclusive. PROGNOSIS: Risk for psychosis was 10.4% (95%CI: 5.8%-18.1%) at 6 months, 20% (95%CI: 15%-26%) at 12 months, 23% (95%CI: 18%-29%) at 24 months and 23.3% (95%CI: 17.3%-30.7%) at ?36 months. INTERVENTIONS: There was not enough evidence to recommend one specific treatment (including cognitive behavioural therapy) over the others (including control conditions) to prevent the transition to psychosis in this population. Randomised controlled trials suggested that family interventions, cognitive remediation and fish oil supplementation may improve cognition, symptoms and functioning. At baseline, 30% of CHR-P adolescents were prescribed antipsychotics and 60% received psychotherapy. CONCLUSIONS: It is possible to detect and formulate a group-level prognosis in adolescents at risk for psychosis. Future interventional research is required. En ligne : http://dx.doi.org/10.1111/jcpp.13322 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=445 [article] Annual Research Review: Prevention of psychosis in adolescents - systematic review and meta-analysis of advances in detection, prognosis and intervention [Texte imprimé et/ou numérique] / Ana CATALAN, Auteur ; Gonzalo SALAZAR DE PABLO, Auteur ; Julio VAQUERIZO SERRANO, Auteur ; Pierluca MOSILLO, Auteur ; Helen BALDWIN, Auteur ; Aranzazu FERNANDEZ-RIVAS, Auteur ; Carmen MORENO, Auteur ; Celso ARANGO, Auteur ; Christoph U CORRELL, Auteur ; Ilaria BONOLDI, Auteur ; Paolo FUSAR-POLI, Auteur . - p.657-673. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 62-5 (May 2021) . - p.657-673 Mots-clés : Psychosis  adolescence  childhood  clinical high-risk state for psychosis  evidence  first-episode  meta-analysis  prediction  prevention  psychosis risk  schizophrenia Index. décimale : PER Périodiques Résumé : BACKGROUND: The clinical high-risk state for psychosis (CHR-P) paradigm has facilitated the implementation of psychosis prevention into clinical practice; however, advancements in adolescent CHR-P populations are less established. METHODS: We performed a PRISMA/MOOSE-compliant systematic review of the Web of Science database, from inception until 7 October 2019, to identify original studies conducted in CHR-P children and adolescents (mean age <18 years). Findings were systematically appraised around core themes: detection, prognosis and intervention. We performed meta-analyses (employing Q statistics and I (2) test) regarding the proportion of CHR-P subgroups, the prevalence of baseline comorbid mental disorders, the risk of psychosis onset and the type of interventions received at baseline. Quality assessment and publication bias were also analysed. RESULTS: Eighty-seven articles were included (n = 4,667 CHR-P individuals). Quality of studies ranged from 3.5 to 8 (median 5.5) on a modified Newcastle-Ottawa scale. Detection: Individuals were aged 15.6 ± 1.2 years (51.5% males), mostly (83%) presenting with attenuated positive psychotic symptoms. CHR-P psychometric accuracy improved when caregivers served as additional informants. Comorbid mood (46.4%) and anxiety (31.4%) disorders were highly prevalent. Functioning and cognition were impaired. Neurobiological studies were inconclusive. PROGNOSIS: Risk for psychosis was 10.4% (95%CI: 5.8%-18.1%) at 6 months, 20% (95%CI: 15%-26%) at 12 months, 23% (95%CI: 18%-29%) at 24 months and 23.3% (95%CI: 17.3%-30.7%) at ?36 months. INTERVENTIONS: There was not enough evidence to recommend one specific treatment (including cognitive behavioural therapy) over the others (including control conditions) to prevent the transition to psychosis in this population. Randomised controlled trials suggested that family interventions, cognitive remediation and fish oil supplementation may improve cognition, symptoms and functioning. At baseline, 30% of CHR-P adolescents were prescribed antipsychotics and 60% received psychotherapy. CONCLUSIONS: It is possible to detect and formulate a group-level prognosis in adolescents at risk for psychosis. Future interventional research is required. En ligne : http://dx.doi.org/10.1111/jcpp.13322 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=445

Oxytocin Exposure in Labor and its Relationship with Cognitive Impairment and the Genetic Architecture of Autism / Alicia GARCIA-ALCON in Journal of Autism and Developmental Disorders, 53-1 (January 2023)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 53-1 (January 2023) . - p.66-79 Titre : Oxytocin Exposure in Labor and its Relationship with Cognitive Impairment and the Genetic Architecture of Autism Type de document : Texte imprimé et/ou numérique Auteurs : Alicia GARCIA-ALCON, Auteur ; Javier GONZALEZ-PENAS, Auteur ; Elisa WECKX, Auteur ; M. J. PENZOL, Auteur ; Xaquin GURRIARAN, Auteur ; Javier COSTAS, Auteur ; Covadonga M. DIAZ-CANEJA, Auteur ; Carmen MORENO, Auteur ; Patricia HERNANDEZ, Auteur ; Celso ARANGO, Auteur ; Mara PARELLADA, Auteur Article en page(s) : p.66-79 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : Whether there is a relationship between oxytocin (OXT) use in labor and the risk of autism (ASD), and the nature of such relationship, is unclear. By integrating genetic and clinical data in a sample of 176 ASD participants, we tested the hypothesis that OXT is a marker for abnormal prenatal development which leads to impairments in the process of labor. OXT-exposed ASD had more obstetric complications (P=0.031), earlier onset of symptoms (P=0.027), poorer cognitive development (P=0.011), higher mutation burden across neurodevelopment genes (P=0.020; OR=5.33) and lower transmission of polygenic risk for ASD (P=0.0319), than non-exposed ASD. OXT seems to constitute a risk indicator rather than a risk factor for ASD, which is relevant for diagnostic and genetic counselling. En ligne : https://doi.org/10.1007/s10803-021-05409-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=492 [article] Oxytocin Exposure in Labor and its Relationship with Cognitive Impairment and the Genetic Architecture of Autism [Texte imprimé et/ou numérique] / Alicia GARCIA-ALCON, Auteur ; Javier GONZALEZ-PENAS, Auteur ; Elisa WECKX, Auteur ; M. J. PENZOL, Auteur ; Xaquin GURRIARAN, Auteur ; Javier COSTAS, Auteur ; Covadonga M. DIAZ-CANEJA, Auteur ; Carmen MORENO, Auteur ; Patricia HERNANDEZ, Auteur ; Celso ARANGO, Auteur ; Mara PARELLADA, Auteur . - p.66-79. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 53-1 (January 2023) . - p.66-79 Index. décimale : PER Périodiques Résumé : Whether there is a relationship between oxytocin (OXT) use in labor and the risk of autism (ASD), and the nature of such relationship, is unclear. By integrating genetic and clinical data in a sample of 176 ASD participants, we tested the hypothesis that OXT is a marker for abnormal prenatal development which leads to impairments in the process of labor. OXT-exposed ASD had more obstetric complications (P=0.031), earlier onset of symptoms (P=0.027), poorer cognitive development (P=0.011), higher mutation burden across neurodevelopment genes (P=0.020; OR=5.33) and lower transmission of polygenic risk for ASD (P=0.0319), than non-exposed ASD. OXT seems to constitute a risk indicator rather than a risk factor for ASD, which is relevant for diagnostic and genetic counselling. En ligne : https://doi.org/10.1007/s10803-021-05409-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=492

Practitioner Review: Long-term pharmacological treatment of pediatric bipolar disorder / Covadonga M. DIAZ-CANEJA in Journal of Child Psychology and Psychiatry, 55-9 (September 2014)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 55-9 (September 2014) . - p.959-980 Titre : Practitioner Review: Long-term pharmacological treatment of pediatric bipolar disorder Type de document : Texte imprimé et/ou numérique Auteurs : Covadonga M. DIAZ-CANEJA, Auteur ; Carmen MORENO, Auteur ; Cloe LLORENTE, Auteur ; Ana ESPLIEGO, Auteur ; Celso ARANGO, Auteur ; Dolores MORENO, Auteur Article en page(s) : p.959-980 Langues : Anglais (eng) Mots-clés : Bipolar  mania  maintenance  mood stabilizer  antipsychotic  child  adolescent Index. décimale : PER Périodiques Résumé : Background Although long-term treatment is a core aspect of the management of children and adolescents with bipolar disorder (BD), most clinical recommendations are based on results from short-term studies or adult data. In order to guide clinical practice, we review the efficacy and safety profile of mood stabilizers, antipsychotics, and other pharmacological strategies for the long-term treatment of BD in pediatric patients. Methods A MEDLINE, EMBASE, Cochrane and PsycInfo search (inception through November 2013) was performed to identify prospective studies longer than 12 weeks assessing the use of pharmacological strategies for the long-term treatment of BD in pediatric patients (0–18 years of age). Results Four randomized controlled trials (RCT) [three placebo-controlled (assessing aripiprazole (2) and flax oil), and one head-to-head comparison of lithium vs. divalproex], and thirteen noncontrolled studies (six open-label studies assessing lithium or anticonvulsants, five assessing second-generation antipsychotics (SGAs) and four assessing combination strategies) were included in the review. Aripiprazole has shown efficacy for relapse prevention in children with pediatric bipolar disorder (PBD) 4–9 years of age in one placebo-controlled RCT. Positive results have been reported in noncontrolled studies with quetiapine and lithium for relapse prevention, as well as with lithium, quetiapine, ziprasidone, and the combination of risperidone and divalproex or lithium for long-term symptom reduction in PBD. The most frequently reported adverse events in children and adolescents treated with lithium and anticonvulsants are gastrointestinal and neurological, whereas use of SGAs is mainly related to weight gain and sedation. Conclusion According to the limited empirical evidence, aripiprazole can be useful for relapse prevention in children with PBD. Given the lack of consistent efficacy data, clinical decision making should be based on individual clinical aspects and safety concerns. En ligne : http://dx.doi.org/10.1111/jcpp.12271 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=238 [article] Practitioner Review: Long-term pharmacological treatment of pediatric bipolar disorder [Texte imprimé et/ou numérique] / Covadonga M. DIAZ-CANEJA, Auteur ; Carmen MORENO, Auteur ; Cloe LLORENTE, Auteur ; Ana ESPLIEGO, Auteur ; Celso ARANGO, Auteur ; Dolores MORENO, Auteur . - p.959-980. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 55-9 (September 2014) . - p.959-980 Mots-clés : Bipolar  mania  maintenance  mood stabilizer  antipsychotic  child  adolescent Index. décimale : PER Périodiques Résumé : Background Although long-term treatment is a core aspect of the management of children and adolescents with bipolar disorder (BD), most clinical recommendations are based on results from short-term studies or adult data. In order to guide clinical practice, we review the efficacy and safety profile of mood stabilizers, antipsychotics, and other pharmacological strategies for the long-term treatment of BD in pediatric patients. Methods A MEDLINE, EMBASE, Cochrane and PsycInfo search (inception through November 2013) was performed to identify prospective studies longer than 12 weeks assessing the use of pharmacological strategies for the long-term treatment of BD in pediatric patients (0–18 years of age). Results Four randomized controlled trials (RCT) [three placebo-controlled (assessing aripiprazole (2) and flax oil), and one head-to-head comparison of lithium vs. divalproex], and thirteen noncontrolled studies (six open-label studies assessing lithium or anticonvulsants, five assessing second-generation antipsychotics (SGAs) and four assessing combination strategies) were included in the review. Aripiprazole has shown efficacy for relapse prevention in children with pediatric bipolar disorder (PBD) 4–9 years of age in one placebo-controlled RCT. Positive results have been reported in noncontrolled studies with quetiapine and lithium for relapse prevention, as well as with lithium, quetiapine, ziprasidone, and the combination of risperidone and divalproex or lithium for long-term symptom reduction in PBD. The most frequently reported adverse events in children and adolescents treated with lithium and anticonvulsants are gastrointestinal and neurological, whereas use of SGAs is mainly related to weight gain and sedation. Conclusion According to the limited empirical evidence, aripiprazole can be useful for relapse prevention in children with PBD. Given the lack of consistent efficacy data, clinical decision making should be based on individual clinical aspects and safety concerns. En ligne : http://dx.doi.org/10.1111/jcpp.12271 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=238

Psychopathology in Children and Adolescents with ASD Without Mental Retardation / Marta CAAMANO in Journal of Autism and Developmental Disorders, 43-10 (October 2013)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 43-10 (October 2013) . - p.2442-2449 Titre : Psychopathology in Children and Adolescents with ASD Without Mental Retardation Type de document : Texte imprimé et/ou numérique Auteurs : Marta CAAMANO, Auteur ; Leticia BOADA, Auteur ; Jessica MERCHAN-NARANJO, Auteur ; Carmen MORENO, Auteur ; Cloe LLORENTE, Auteur ; Dolores MORENO, Auteur ; Celso ARANGO, Auteur ; Mara PARELLADA, Auteur Article en page(s) : p.2442-2449 Langues : Anglais (eng) Mots-clés : Asperger syndrome  Psychopathology  Comorbidity  Adolescent  Developmental disorders Index. décimale : PER Périodiques Résumé : This study analyzes subclinical psychopathology in children and adolescents with autism spectrum disorders (ASD) without mental retardation with no comorbid disorder, assessed by an extensive general psychopathology interview. The K-SADS-PL was administered to a group of 25 patients with ASD (mean age = 12.80 ± 2.86 years) and 25 healthy controls (mean age 12.52 ± 2.86 years). Significant differences were found between patients with ASD and controls for the domains of: depressive disorder, anxiety separation disorder, agoraphobia and specific phobias, obsessive compulsive disorder (OCD), and attention deficit hyperactivity disorder (ADHD). In patients without a comorbid disorder, we found a profile of subclinical disturbances that suggest high risk for comorbid psychiatric conditions derived from the presence of subthreshold symptomatology. En ligne : http://dx.doi.org/10.1007/s10803-013-1792-0 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=215 [article] Psychopathology in Children and Adolescents with ASD Without Mental Retardation [Texte imprimé et/ou numérique] / Marta CAAMANO, Auteur ; Leticia BOADA, Auteur ; Jessica MERCHAN-NARANJO, Auteur ; Carmen MORENO, Auteur ; Cloe LLORENTE, Auteur ; Dolores MORENO, Auteur ; Celso ARANGO, Auteur ; Mara PARELLADA, Auteur . - p.2442-2449. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 43-10 (October 2013) . - p.2442-2449 Mots-clés : Asperger syndrome  Psychopathology  Comorbidity  Adolescent  Developmental disorders Index. décimale : PER Périodiques Résumé : This study analyzes subclinical psychopathology in children and adolescents with autism spectrum disorders (ASD) without mental retardation with no comorbid disorder, assessed by an extensive general psychopathology interview. The K-SADS-PL was administered to a group of 25 patients with ASD (mean age = 12.80 ± 2.86 years) and 25 healthy controls (mean age 12.52 ± 2.86 years). Significant differences were found between patients with ASD and controls for the domains of: depressive disorder, anxiety separation disorder, agoraphobia and specific phobias, obsessive compulsive disorder (OCD), and attention deficit hyperactivity disorder (ADHD). In patients without a comorbid disorder, we found a profile of subclinical disturbances that suggest high risk for comorbid psychiatric conditions derived from the presence of subthreshold symptomatology. En ligne : http://dx.doi.org/10.1007/s10803-013-1792-0 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=215

---

1 (1 - 4 / 4)